Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individualâs immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļVRAX
āļāļ·āđāļāļāļĢāļīāļĐāļąāļVirax Biolabs Group Ltd
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 14, 2022
āļāļĩāļāļĩāđāļFoster (James)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ19
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJul 14
āļāļĩāđāļāļĒāļđāđBiocity Glasgow
āđāļĄāļ·āļāļLONDON
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited Kingdom
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđML1 5UH
āđāļāļĢāļĻāļąāļāļāđ4402077887414
āđāļ§āđāļāđāļāļāđhttps://www.viraxbiolabs.com
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļVRAX
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 14, 2022
āļāļĩāļāļĩāđāļFoster (James)